DURECT Corp. (DRRX:NASDAQ) announced in a news release the topline results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis.
Whereas DUR-928 was well tolerated with no adverse events occurring, it failed to demonstrate any benefit over the placebo in either the primary or secondary analyses. Thus, DURECT will curtail its development of DUR-928 for psoriasis.
Twenty-two patients completed the U.S.-based Phase 2a psoriasis study. They applied DUR-928 topically to the plaque on one of their arms and applied a placebo to a similar plaque on their other arm daily for 28 days. Patients were followed for four weeks after the final application.
Going forward, DURECT will focus on advancing DUR-928 in nonalcoholic steatohepatitis (NASH) and alcoholic hepatitis in 2020. The biopharma will finish its NASH trial in H1/20 and commence the Phase 2b alcoholic hepatitis study in mid-2020.
Read what other experts are saying about:
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: DURECT Corp. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
